Michael C Gundry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8930468/publications.pdf

Version: 2024-02-01



MICHAEL C GUNDRY

#	Article	IF	CITATIONS
1	Single-cell damagenome profiling unveils vulnerable genes and functional pathways in human genome toward DNA damage. Science Advances, 2021, 7, .	10.3	12
2	Modeling <i>IKZF1</i> lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. Blood Advances, 2021, 5, 3876-3890.	5.2	6
3	Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion. Cell Stem Cell, 2020, 27, 326-335.e4.	11.1	25
4	Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Advances, 2020, 4, 3357-3367.	5.2	27
5	It's All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice. Cancer Cell, 2020, 37, 267-269.	16.8	20
6	New insights into the biology of acute myeloid leukemia with mutated NPM1. International Journal of Hematology, 2019, 110, 150-160.	1.6	30
7	Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Journal of Visualized Experiments, 2018, , .	0.3	23
8	Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell, 2018, 34, 499-512.e9.	16.8	209
9	Forniceal deep brain stimulation induces gene expression and splicing changes that promote neurogenesis and plasticity. ELife, 2018, 7, .	6.0	39
10	Precise Modeling of IKZF1 Alterations in Human B-Cell Acute Lymphoblastic Leukemia Cell Lines Reveals Distinct Chemosensitivity, Homing, and Engraftment Properties. Blood, 2018, 132, 549-549.	1.4	1
11	DNMT3A in Leukemia. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030320.	6.2	135
12	Nuclear relocalization of mutant NPM1 induces downregulation of Hox/Meis1, terminal differentiation, and cell cycle arrest. Experimental Hematology, 2017, 53, S45.	0.4	1
13	Technical considerations for the use of CRISPR/Cas9 in hematology research. Experimental Hematology, 2017, 54, 4-11.	0.4	18
14	Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nature Communications, 2017, 8, 16026.	12.8	158
15	DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biology, 2017, 18, 176.	8.8	153
16	Abstract 3841: A hybrid mapping approach improves genomic and transcriptomic analysis of patient derived orthotropic xenograft (PDOX) models of pediatric CNS tumors. , 2017, , .		0
17	Abstract 1031: Nuclear relocalization of NPM1c induces terminal differentiation and cell growth arrest. , 2017, , .		0
18	Acute Myeloid Leukemia with Mutated <i>NPM1</i> Is Dependent on the Cytoplasmic Localization of NPM1c. Blood, 2017, 130, 877-877.	1.4	0

MICHAEL C GUNDRY

#	Article	IF	CITATIONS
19	Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Cell Reports, 2016, 17, 1453-1461.	6.4	223
20	DNA Epigenome Editing Using Crispr-Cas Suntag-Directed DNMT3A. Blood, 2016, 128, 2707-2707.	1.4	3
21	Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19. Blood, 2016, 128, 4560-4560.	1.4	4
22	Crispr Engineering in CD34+ Progenitors Reveals Cis-Acting Regulatory Regions Mediating 3D Interactions and Stem Cell Fate Decisions. Blood, 2016, 128, 1466-1466.	1.4	0
23	Fast and Efficient Gene Editing in Human Hematopoietic Cells. Blood, 2016, 128, 4704-4704.	1.4	0
24	5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1. Oncogene, 2012, 31, 5172-5179.	5.9	54
25	Direct, genome-wide assessment of DNA mutations in single cells. Nucleic Acids Research, 2012, 40, 2032-2040.	14.5	68
26	Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variants. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 729, 1-15.	1.0	75